Aging stops being a vibe and becomes a to-do list

Aging stops being a vibe and becomes a to-do list

A new PubMed review reframes aging not as fate but as a set of targetable mechanisms. The field is increasingly going upstream—attacking core processes rather than mopping up downstream disease. The strategies on the list: senolytics such as dasatinib + quercetin, senomorphics such as rapamycin, and senoreversion via epigenetic reprogramming. Caloric restriction mimetics—spermidine, α-ketoglutarate, ergothioneine—also make the cut, alongside AI-driven multiomics and personalized intervention design.

Gobble's Take: Aging now has a menu. It's long, it's messy, and nobody's finished ordering yet. Source: PubMed

Longevity media admits the field is moving faster than anyone can read

The Longevity Digest doesn't ease you in. Its opening line is a flat confession: the field moves fast—too fast for most people to track every breakthrough, every protocol update, every researcher's latest findings. From there it pivots straight into GLP-1 territory. Oral semaglutide demands strict fasting with ≤4 oz of water and a 30-minute hold before anything else—a real-world adherence test. Dose switching is not plug-and-play. After 36 weeks on tirzepatide, patients switched to placebo had regained around 14% of body weight by week 88. Roughly 17% held on to most of their loss. The rest did not.

Gobble's Take: The story isn't "miracle drug." It's "congratulations, you have a new chronic condition to manage." Source: The Longevity Digest

In Case You Missed It

Yesterday's top stories:

• Rewinding liver age one gene at a time
• The brain’s aging split: APOE2 repairs, APOE4 frays
• Senescence is still the big target, and the toolbox is getting crowded
• David Sinclair’s longevity thesis in one sentence: aging is negotiable